Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
about
miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.What pelvic radiation disease symptoms are experienced by patients receiving external beam radiotherapy and a high-dose-rate brachytherapy boost for prostate cancer?Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.Contrast-enhanced magnetic resonance imaging with a novel nano-size contrast agent for the clinical diagnosis of patients with lung cancer.
P2860
Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Five-year biochemical recurren ...... lly localized prostate cancer.
@en
type
label
Five-year biochemical recurren ...... lly localized prostate cancer.
@en
prefLabel
Five-year biochemical recurren ...... lly localized prostate cancer.
@en
P2093
P1433
P1476
Five-year biochemical recurren ...... lly localized prostate cancer.
@en
P2093
Alessandro Larcher
Andreas Krüll
Derya Tilki
Hans Lesmana
Jonas Schiffmann
Katharina Boehm
Markus Graefen
Philipp Mandel
Pierre I Karakiewicz
Rudolf Schwarz
P304
P356
10.1016/J.UROLONC.2015.09.012
P577
2015-10-22T00:00:00Z